Puma Biotechnology (PBYI) Osake Kurssi
Puma Biotechnology Kurssi
Viimeisten 8 vuoden aikana Puma Biotechnologyn liikevaihto kasvoi 30,2 % vuodessa ja ylsi 228,37 M USD:een. Osakekohtainen tulos on kasvanut 2 300,5 % vuodessa viimeisten 3 vuoden aikana. Puma Biotechnologyn nettomarginaali 13,6 % on noussut verrattuna −11,5 %:iin muutama vuosi sitten. Puma Biotechnologyn 12 kuukauden konsensustavoitehinta on 5,10 USD, noin ali kurssia 51,3 %. 6 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Myy.
Puma Biotechnology osakekurssi
Puma Biotechnology liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Puma Biotechnology -osakkeesta
The business model of Puma Biotechnology Inc. is focused on developing and commercializing innovative treatments for cancer. The company specializes in the research and development of targeted therapies that aim to address specific types of cancer, such as HER2-positive breast cancer. Puma Biotechnology Inc. is committed to advancing the field of oncology through the discovery and development of effective and safe medications. By utilizing its expertise in molecular biology and drug development, the company aims to improve patient outcomes and contribute to the fight against cancer. Puma Biotechnology Inc. strives to create value for its shareholders by bringing novel treatments to market and maintaining a strong pipeline of innovative therapies.
Puma Biotechnology Inc is primarily active in the biotechnology industry.
The main competitors of Puma Biotechnology Inc in the market include well-established pharmaceutical companies such as Pfizer, Novartis, and Roche. These companies also focus on developing and commercializing innovative treatments for various diseases, including cancer. Puma Biotechnology Inc faces competition in its targeted therapy segment, particularly in the field of HER2-positive breast cancer treatment, where these competitors have their own competing products. However, Puma Biotechnology Inc's unique drug development pipeline and its focus on personalized medicine allow it to differentiate itself in the market.
Puma Biotechnology Inc. is a renowned biopharmaceutical company with a rich history and background. Established in 2010, Puma Biotechnology primarily focuses on the development and commercialization of innovative therapeutics to treat various forms of cancer. Headquartered in Los Angeles, California, the company has successfully developed and received approvals for its flagship product, Nerlynx (neratinib), which is utilized in the treatment of HER2-positive breast cancer. Recognized for its cutting-edge research and development efforts, Puma Biotechnology strives to provide advanced treatment options and improve the lives of cancer patients worldwide. With a commitment to pioneering medical breakthroughs, Puma Biotechnology continues to leave a significant impact in the field of oncology.
Puma Biotechnology Inc has achieved several significant milestones. One of the notable achievements includes the successful development and commercialization of Nerlynx (neratinib), an FDA-approved treatment for HER2-positive breast cancer. Additionally, Puma Biotechnology Inc has made substantial progress in conducting clinical trials and expanding the indications for Nerlynx. The company has also advanced its research pipeline, collaborating with leading institutions to explore potential therapies for various types of cancer. Puma Biotechnology Inc's commitment to innovation and patient-centric approach has positioned them as a key player in the biotechnology industry.
Puma Biotechnology Inc is primarily present in the United States.
Puma Biotechnology Inc represents a strong commitment to improving the lives of patients battling cancer. The company's corporate philosophy centers around advancing innovative treatments and therapies to combat various forms of cancer. Puma Biotechnology is dedicated to conducting rigorous research and development to bring effective, cutting-edge medicines to market. With a focus on personalized medicine, Puma Biotechnology strives to tailor treatments to patients' specific needs, enhancing their chances of positive outcomes. By harnessing scientific advancements and collaborating with leading experts, Puma Biotechnology remains steadfast in its mission to make a meaningful impact in the fight against cancer.
Analyytikot asettavat tällä hetkellä Puma Biotechnology-osakkeelle keskimääräisen tavoitehinnan 5,10 USD (mediaani: 5,10 USD), mikä merkitsee −51,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.
6 analyytikkoa arvioi tällä hetkellä Puma Biotechnology-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Puma Biotechnology-yhtiöltä 226,00 M USD liikevaihtoa ja 0,37 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Puma Biotechnology-osake noteerataan hintaan 9,36 EUR (10,48 USD).
Puma Biotechnology-osake (PBYI) on listattuna 1 pörssissä, muun muassa: NASDAQ (PBYI).
Puma Biotechnology Inc is an American biotech company that focuses on the development of innovative cancer therapies. It was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates in two business segments: drug development and commercialization of drugs. The primary business unit focuses on the development of cancer drugs. The flagship product of Puma Biotechnology is Neratinib, an oral cancer medication used for the treatment of HER2-positive breast cancer. Other clinical studies are also underway, including PB272, another oral cancer medication for the treatment of HER2-positive breast cancer and other types of cancer. In addition to drug development, Puma Biotechnology also engages in the commercialization of drugs, marketing Neratinib in the US, Europe, and Asia in collaboration with various partners. The company works closely with medical communities and patient organizations to raise awareness of the latest treatment options and increase the availability of medications in different countries. Puma Biotechnology also collaborates with scientific and clinical organizations to advance the development of innovative cancer therapies. The company aims to develop and bring to market patient-centric cancer therapies that can improve the quality of life for cancer patients. Puma Biotechnology plans to increase its research and development activities, expand its product range to cover more types of cancer, and expand into new markets while increasing production capacity to meet higher demand for its products. Overall, Puma Biotechnology Inc has a strong business model based on successful development of cancer medications and a strong commercial presence. The company's future prospects are promising as it focuses on the direct needs of cancer patients and strives to develop innovative therapies that have the potential to improve the lives of millions of patients worldwide.
odotettu liikevaihto Puma Biotechnology on 226,00 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Puma Biotechnology on 19,15 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Puma Biotechnology:n hinta-voitto-suhde (P/E) on tällä hetkellä 28,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Puma Biotechnology-osakkeen arvostusta.
Puma Biotechnology:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,39. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Puma Biotechnology-osakkeen arvostuskennuslukuna.
Puma Biotechnology:n Eulpool-laatuscore on 5/10.
Puma Biotechnology:n ISIN on US74587V1070. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Puma Biotechnology:n WKN on A1J643. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Puma Biotechnology:n ticker on PBYI. Tämä pörssinoteeraus käytetään Puma Biotechnology-osakkeiden kauppaan pörssissä.
Puma Biotechnology osake
Puma Biotechnology vertaisryhmä
Puma Biotechnology Ticker
Puma Biotechnology FIGI
Kaikki tunnusluvut ja syvällinen analyysi Puma Biotechnology:sta
Meidän osakeanalyysimme Puma Biotechnology-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Puma Biotechnology:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: